How the Office 365 version of Excel 2016 differs from previous versions and step-by-step how to use them?

Restoring the Workbook Sharing and Track Changes commands that have vanished in certain builds of Office 365.


Microsoft Excel is one of the most preferred spreadsheets used in the corporate world, as well as individually, having displaced Lotus about a quarter of a century ago. Its latest version, MS Excel Office 365 version, was released in 2016. This version differs from earlier ones in many ways. To start with, the latest version is no longer identical for all users. Other novelties include:

  • More access to what other authors are doing in other MS programs such as Word, PowerPoint and OneNote;
  • Ability to attach files from OneDrive and to automatically configure permissions
  • Option of freedom in reviewing, editing, analyzing, and presenting Office 2016 documents from around a wide variety of devices, including PC, Mac, android phones and tablets.

A complete explanation of these new features, and more importantly, how to use them for quicker work, will be offered at a webinar that is being organized by Compliance4All, a leading provider of professional trainings for all the areas of regulatory compliance. David Ringstrom, a leading, globally known expert on MS Excel, will be the speaker at this webinar.

Want to gain mastery of using MS Excel 2016? Then, please enroll for this webinar by visiting


The aim of this webinar, which is essentially about how the Office 365 version of Excel 2016 differs from previous versions and perpetual licensed versions of Excel 2016; is to help participants get a complete understanding of the ways by which to understand and optimize the uses of MS Excel 2016.

Full understanding of the latest version of MS Excel

At this webinar, the speaker will explain the ways in which the 2016 version has been updated with new features. He will describe worksheet functions in a step-by-step manner of how to use them. David will also show important keyboard shortcuts and tips, which will reduce the time needed to work on this program.

David will help the participants of this webinar overcome the frustrations of not getting the functions right. The highlight of this webinar is the teaching methodology that David will adapt: he will first show each technique on a PowerPoint slide with numbered steps, and, will later repeat the same for Office 365. He will thus demonstrate each technique twice. Also explained at this webinar is the differences in the perpetual licensed versions of Excel 2016, 2013, 2010, or 2007, for which he will hand over detailed handouts and an Excel workbook that includes most of the examples that he will use during this webinar.


David will cover the following areas at this webinar:

  • Determining if you have the subscription-based Office 365 version of Excel or a perpetually licensed version
  • Discovering new worksheet functions available in Excel 2016
  • Learning about the MAXIFS function available in the Office 365 version of Excel 2016
  • Learning about the MINIFS function available in the Office 365 version of Excel 2016, as well as how to use the MIN function as an array formula that will achieve the same effect in any version of Excel
  • Discovering the Recommended PivotTables feature
  • Exploring pivot table options that can only be set in the Office 365 version of Excel 2016
  • Mapping geographic data with just a couple of mouse clicks in the Office 365 version of Excel 2016
  • Embedding 3D models into Office 365 spreadsheets, while seeing what’s viewable in other versions of Excel
  • Using the Icons command in Office 365 to add emoji-style icons within spreadsheets
  • Seeing the benefits and risks of sharing workbooks via OneDrive in Office 365
  • Restoring the Workbook Sharing and Track Changes commands that have vanished in certain builds of Office 365
  • Providing feedback about the Office 365 version of Microsoft Excel directly from within the application
  • Using Microsoft’s free Excel Online service to view and edit spreadsheets that use features from Office 365 that aren’t compatible with other versions of Excel.

How can a Culture of Quality and Compliance Impact your Company’s Success?

At this very important learning session on Quality, Suzanne will cover all the perspectives of Quality.

If there is one attribute that sits at the very core of an organization, it has to be Quality. If Quality is this critical to organizations; then, what is Quality in the context of an organization?  If Philip Crosby defined Quality as conformance to requirements and Sam Walton considered it as being able to give the customers what they want; William A. Foster explained Quality in an organization in the following words: “Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction and skillful execution. It represents the wise choice of many alternatives”.

Those in charge of Quality in organizations have to consider many questions relating to it. These are some of them: do we consider it an attribute or characteristic in relation to a certain standard or customer requirement? Is it all about achieving a state where our product is free from defects? Is it a system that we create for holding inspection standards or making the Quality System accountable to? Or is there something beyond all these?

Quality should become part of the organization’s culture

If there is one truly critical work that an organization has to carry out to become successful and to stay ahead; it is to imbibe Quality into its very core. Going beyond the semantics; Quality should become a way of life for the organization. it should become a philosophy, an inalienable part of its culture, and a habit. For organizations to meet and exceed customer expectations all the time and every time, Quality has to be implanted into the very essence of an organization.

Compliance4All, a well-known provider of professional trainings for the areas of regulatory compliance, explain all the elements of Quality at a webinar that it is organizing. Susanne Manz, a highly regarded leader in the medical device industry, who emphasizes Quality, compliance, and Six Sigma, and who brings extensive background in Quality and compliance for medical devices from new product development, to operations, to post-market activities, will be the speaker at this webinar.

Please register for this webinar by visiting

Quality from all perspectives

At this very important learning session on Quality, Suzanne will cover all the perspectives of Quality. Among the important learning objectives of this session is to teach participants to identify the warning signals that indicate that there could be Quality issues within the organization and the risks the organization faces from Quality and compliance issues. Participants will understand the ways of changing their organizations from being reactive to becoming proactive. Participants will understand how a culture of Quality and compliance can impact their organization’s success, and will learn the ways of creating a culture of Quality and compliance at all levels in their organization.

Suzanne will cover the following areas at this webinar:

  • FDA and NB expectations for Quality Systems
  • Lessons Learned from 483s and warning letters
  • How culture can impact Quality and compliance risk
  • Management commitment and responsibility
  • Maturity Modeling
  • Key capabilities
  • Roles and responsibilities
  • Quality planning and strategy
  • Tools and techniques
  • Best Practices.

What is FDA regulation of combination products?

Different parts of the combination product meet different proprietary purposes or serve different kinds of benefits.

First, what is a combination product? FDA’s 21 CFR 3.2 (e) describes a combination product as a product that has any of these combinations: a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and a biological product.

Lines of distinction are blurring

With the recent technological advancements in the way drugs are combined; there has been a steady increase in the number of combination products the FDA has been getting and expects to receive for review. Historically, the FDA’s medical product centers, such as the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH) have been tasked with the approval of combination products. However, in the near future, FDA regulation of combination products is likely to undergo a vast change, as strict segregation of these bodies has given rise to challenges related to regulation, policy, and review that need to be addressed.


FDA regulation of combination products covers all aspects of the development and management of combination products, such as clinical investigation, pre-clinical testing, manufacturing and quality control, marketing applications, promotion and advertising,adverse event reporting, and post-approval modifications.

Marketing applications are the backbone of FDA regulation of combination productsFDA regulation of combination products requires all combination products to fulfill marketing applications. This is what enables it to be certified as fit for marketing. A single marketing application or separate one can be made for different parts of the combination product, for its marketing application to get approved.

In most cases, more than one marketing application gets filed when the different parts of the combination product meet different proprietary purposes or serve different kinds of benefits. It is also possible that when any of the individual parts making up a combination product has already been approved for another use, multiple marketing applications are made out as part of FDA regulation of combination products.

Facebook spoke with hospitals about matching health data to anonymized profiles

Hospital may want to send a nurse to check in on them while recovering from a surgery.

Facebook began speaking with hospitals last year about the possibility of matching anonymized user profiles with health data in an effort to improve medical care, according to a CNBC report exposing the program. Facebook confirmed its work to CNBC but said it had hit “pause” on the program last month — presumably following the Cambridge Analytica scandal — to focus on “doing a better job of protecting people’s data” and being clearer about how it’s used.

The plan had been to get hospitals to share anonymized medical information — such as health issues and age, but not name — and match it up with anonymized Facebook accounts that appeared to belong to those same people, according to the report. It would then somehow use insights from users’ Facebook behavior to inform medical treatments. In one example CNBC gives, it says Facebook might have determined that an elderly user didn’t have many local friends, so a hospital may want to send a nurse to check in on them while recovering from a surgery.


In a statement to CNBC, Facebook said, “This work has not progressed past the planning phase, and we have not received, shared, or analyzed anyone’s data.”

Though the report makes it sound like the data would be customized to specific patients, Facebook said in an email to The Verge that it would instead be used more generally. “The project would not attempt to provide health recommendations for specific people,” a spokesperson said. “Instead the focus would be on producing general insights that would help medical professionals take social connectedness into account as they develop treatment or intervention programs for their patients.”

This probably wasn’t a great idea even without the privacy scandal from Cambridge Analytica engulfing the company. Essentially, Facebook proposed collecting medical data without users’ permission, then secretly pairing it to their profiles. That is an immense violation of privacy.

Though Facebook was going through medical channels to receive the data — it was in talks with organizations including the Stanford Medical School and the American College of Cardiology, according to CNBC — it sounded like patients would not have needed to consent to their information being shared.

Facebook tells us that there would have been no “de-anonymizing of data” and that data “access would theoretically be limited to select people from Facebook and our medical research partners at the [American College of Cardiology].”

Don’t waste your time click the link to continue for full article

Facebook’s data scandal should be a wake-up call about our online footprint

The Facebook episode should be a wake-up call for people when it comes to learning about the information out there about them.

Believe it or not, something good for consumers could come out of the Facebook data scandal.

To recap, a quiz app harvested 50 million Facebook profiles for data which were then sent over to Cambridge Analytica, a firm that was caught claiming it handled the digital aspects of President Donald Trump’s 2016 election campaign.

The data was collected from people without their knowledge, but Facebook said that users had their privacy settings on to allow it.

Even as someone who covers technology extensively, it was a real eye-opener seeing what information Facebook is collecting, even though we give it permission to by signing up, then checking in to a place, or uploading a picture. Like many, I have recently downloaded a file that contains the information Facebook holds about me.

And on the weekend, Ars Technica highlighted a tweet from New Zealand man Dylan McKay who posted a picture of his call history with his partner’s mum that Facebook had collected. On Sunday, the social network said this was done with users’ permission.

This is the problem: We download apps and allow services to collect information about us without a second thought. The good to come out of this Facbeook episode is that people get smarter about their online footprint.

Users should be checking what data services have access to. It’s not just Facebook of course, other big technology firms are in the business of collecting data which is central to their business models.

The Facebook episode should be a wake-up call for people when it comes to learning about the information out there about them. And it seems to be so. An article on CNBC titled “How to download a copy of everything Facebook knows about you,” which was written last week, was still one of the top read pieces on our site Monday.

But the onus is not just on users. Big tech firms need to step up. When a user is signing up for a service or downloading an app, the information being collected and how it will be used needs to be clearly stated. And it must be easy for users to change how their data is accessed.   Here to go to read full article.

Brain back-up start-up ‘will be the death of users’

Imagine a world where you can successfully map and pinpoint a specific memory within your brain,” the site reads.

Nectome has said it will one day be capable of scanning the human brain and preserving it, perhaps running a deceased person’s mind as a computer simulation.

However, its current process requires a fresh brain.

The product is “100% fatal”, the team behind it told MIT Technology Review.

The company is backed by Y Combinator, an organisation that picks a group of new companies each year to fund and mentor in the hope they receive major funding further down the line.

According to the company’s website, Nectome claims it will one day be possible to survey the brain’s connectome – the neural connections within the brain – to such a detailed degree that it will be able to reconstruct a person’s memories even after they have died.

“Imagine a world where you can successfully map and pinpoint a specific memory within your brain,” the site reads.

“Today’s leading neuroscience research suggests that it is possible by preserving your connectome.”


Grant money

Nectome will be part of Y Combinator’s demo days next week – an event where start-ups pitch their new companies to an audience of investors and journalists.

Previous Y Combinator firms include Dropbox and AirBnB.

The firm is also backed by a $960,000 (£687,000) grant from the US National Institute of Mental Health, which said it saw a “commercial opportunity” in brain preservation.

According to MIT Technology Review, the team has consulted lawyers familiar with California’s relatively new laws on dignified end-of-life measures.

The company plans to focus on working with terminally ill people in the testing phase.

The company uses an embalming process to preserve minute details of the brain in microscopic detail.

Its work won a prize for furthering the field of brain preservation when it tried the method on a rabbit.

Taking that further, the team said it had already attempted its technique on a just-deceased woman in Portland, Oregon.

However, even a delay of just a couple of hours meant the brain was already badly damaged, it said.

The next stage is to find someone planning to die via doctor-assisted suicide.

To continue the link for you here

Statement from FDA Commissioner Scott Gottlieb, M.D.,

The FDA takes concerns about Essure very seriously.

Some of my most important time as Commissioner is spent speaking directly to patients and their families about significant health issues that affect their lives, from the devastating opioid crisis to the current flu season. Overseeing a wide array of medical products, the U.S. Food and Drug Administration plays a vital role in providing consumers with up-to-date, evidence-based information to help them make the most informed medical decisions. The products we regulate touch people’s lives in meaningful ways.con-con-1

Last month I had the opportunity to meet with consumers who have been affected by the medical device Essure to listen and learn about their concerns. This device is used as a method of permanent birth control. The product’s manufacturer, Bayer, estimates that more than 750,000 women worldwide have received the device implant since it was first approved by global regulatory authorities. Some of the women I spoke to went on to develop significant medical problems that they ascribe to their use of the product. As a physician, I know that patients are uniquely positioned to provide feedback to the FDA about their experiences with currently available medical products, and I appreciated the thoughtful discussion. Ensuring the safety and effectiveness of medical products is paramount to the FDA and a core part of our consumer protection role. The FDA takes concerns about Essure very seriously.

I would like to outline the steps we’ve taken, to date, regarding this product, and the additional steps that are underway. I also want to reiterate my commitment to regularly communicating with patients and physicians about this device as more information is made available and additional steps are taken.

Since Essure’s approval in 2002, the agency has continued to monitor the product’s safety and effectiveness by reviewing the medical literature, clinical trial information, post-approval study data and medical device reports submitted to the agency. We convened a panel of medical experts in the fall of 2015 to provide us with advice on how we could better understand concerns about the device, such as patients who experienced abdominal pain, abnormal uterine bleeding and device migration.

In February 2016, we ordered the manufacturer of Essure, Bayer, to conduct a postmarketing (522) study to better evaluate the safety profile of this device when used in the real world. We also required a boxed warning to be added to the product labeling as well as a Patient Decision Checklist. The aim is to help make certain that a woman considering Essure receives and has full access to information about the benefits and risks of this type of device prior to undergoing treatment with this product.

As part of the FDA’s ongoing efforts to monitor Essure adverse events, we continue to review medical device reports submitted to our public database and provide updates about our ongoing analysis of the reports on our website. At the current time, the FDA is actively evaluating a significant collection of new medical device reports submitted to FDA on the Essure device. Of the nearly 12,000 reports received in 2017 for Essure, the majority were sent to the FDA in the last quarter of the year.

Detailed Statement enhanced here